Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.72 USD | +2.59% | +14.59% | +113.73% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.93B 161B |
---|---|---|---|---|---|
Net income 2024 * | -241M -20.09B | Net income 2025 * | -308M -25.68B | EV / Sales 2024 * | - |
Net cash position 2024 * | 162M 13.55B | Net cash position 2025 * | 285M 23.77B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.69
x | P/E ratio 2025 * |
-6.97
x | Employees | 328 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.84% |
Latest transcript on Sana Biotechnology, Inc.
1 day | +2.59% | ||
1 week | +14.59% | ||
Current month | -12.80% | ||
1 month | -7.82% | ||
3 months | +59.41% | ||
6 months | +198.63% | ||
Current year | +113.73% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Harr
FOU | Founder | 53 | 13/18/13 |
Nathan Hardy
DFI | Director of Finance/CFO | 48 | 01/18/01 |
Gary Meininger
CTO | Chief Tech/Sci/R&D Officer | - | 10/23/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 01/20/01 | |
Patrick Yang
BRD | Director/Board Member | 75 | 01/18/01 |
Robert Nelsen
FOU | Founder | 60 | 13/18/13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 2 M€ | -.--% | ||
0.05% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 8.72 | +2.59% | 1,612,114 |
25/24/25 | 8.5 | -0.93% | 1,825,504 |
24/24/24 | 8.58 | +6.06% | 1,221,006 |
23/24/23 | 8.09 | +2.02% | 1,688,156 |
22/24/22 | 7.93 | +4.20% | 2,126,514 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+113.73% | 1.93B | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- SANA Stock